C O N T I N U I N G E D U C AT I O N
ince 1962 when the U.S. Food, Drug, and Cosmetic Act was amended, Americans have known that medications in the United States have been subjected to a tremendous amount of research and scrutiny. These efforts have been intended to ensure that both over-the-counter (OTC) and prescription medications were proven safe and effective prior to reaching the U.S. market. With few exceptions, the research and scrutiny has paid off, and serious problems associated with medications have been identified prior to Food and Drug Administration (FDA) approval. The research and analysis that occurs prior to final approval requires enormous amounts of documentation and huge amounts of money even if the medication does not receive FDA approval. Recent estimates for the costs and time associated with the drug-approval process exceed $230 million and more than 12 years to completion. 1 Interestingly, even after the 1962 amendment, natural products (e.g., herbs and other botanicals, vitamins, minerals, amino acids) continued to be sold. Although they were often promoted based on their potential to improve health and increase wellness, they were marketed as foods or food supplements rather than as medicinals, and were often sold in health food stores or in exercise or nutrition centers, and therefore were not subject to the FDA process. In 1993 the FDA reviewed the marketing and sales of these food and food-supplement products and determined that something needed to be done to provide controls. After much research, debate, and even a massive letter-writing campaign by the general public, Congress, rather than the FDA, passed the Dietary Supplement Health and Education Act (DSHEA) of 1994.
In contrast to the process mandated by the 1962 amendment for approval and marketing of medicinal products, the process for marketing a dietary supplement in the United States is streamlined. DSHEA is different from much of the previous legislation and regulations that applies to the FDA. Prior legislation was often intended to protect the consumer from unsafe products or exposure to products with little or no efficacy. DSHEA is based on the concept that "legislative action that protects the right of access of consumers to safe dietary supplements is necessary to promote wellness."
2 It allows natural products such as those derived from plants and animals, vitamins, minerals, and amino acids to be sold as dietary supplements. Under some limited circumstances manufacturers of new dietary supplement ingredients (i.e., never before marketed as a food or food substance) must notify the FDA 75 days before marketing the product and must include safety information for the new ingredient. However, it is generally accepted that dietary supplements can be marketed as long as good man- ufacturing practices are followed and therapeutic claims are not printed on the product label. Under DSHEA, the labeling on dietary supplements must state that the product has not been evaluated by the FDA. Manufacturers are allowed to describe the dietary supplement' s ability to affect "structure or function in humans," and brochures or supplementary documentation may present "a balanced view of the available scientific information." DSHEA does not require that the manufacturer prove the safety or efficacy of their products. Instead, the burden of proof is on the FDA. Under DSHEA, the FDA must prove that a natural product is not safe for human use before it can remove the product from the market.
This streamlined process has made it much less expensive and much easier to market dietary supplements than medications. Therefore, few companies that market these products apply for FDA approval. In some cases, the natural product has been used in folklore or in home or traditional remedies for hundreds or even thousands of years. In many cases the requirements for acquiring a patent to protect the product from competition cannot be met. This lack of protection prevents some companies from investing in the level of product research that would be necessary to meet the FDA requirements for approval of the product through the new-drug approval process. Therefore, only a small number of natural products have ever gone through the FDA new-drug approval process. Two examples of products that are currently marketed as medications are the laxative products senna and cascara.
ss Quality Issues
The effect of DSHEA is that health care organizations and professionals, including managed care organizations (MCOs) and pharmacists, have little assurance that natural products are safe or effective for their patients to use. Therefore, a critical analysis of the available medical literature and product information must be conducted to determine the potential problems and quality issues associated with each natural product. Even the process of using available literature to determine whether each natural product reviewed can be considered reasonably safe and possibly effective to prevent and/or treat disease in humans is difficult. Some of the reasons behind this difficulty are listed in Table 1 , this page.
A major concern related to the lack of rigorous qualitycontrol procedures and standardization is that product content may vary from one batch to another and from one manufacturer to another. Even if manufacturers fully utilize quality-control measures and standardize the major ingredients in their products, some natural products manufacturers cannot be certain that they are controlling just for the actual active ingredient, or that all the potentially active ingredients are contained within their products. For example, there has been debate as to the true active ingredient in St. John' s wort. A group of investigators has recently shown that hyperforin may be the ingredient that gives St. John' s wort its antidepressant activity, but most products available in the United States do not contain enough hyperforin. 3 Unfortunately, all of the studies to date that have attempted to use a standard amount of what was believed to be the active ingredient in St. John' s wort have used products standardized to hypericin. As demonstrated by this example, many of the studies upon which practitioners must depend for current safety and efficacy recommendations may not reflect the true active ingredient(s) of products.
To make matters even more complex, many studies of natural products failed to analyze the ingredients in the products that they were using, and were not able to ensure that the natural product used in the study truly contained the ingredient believed to be under consideration (i.e., the "ginseng" product truly contained ginseng). Studies that have looked at the ingredients of natural products have shown a wide variation in the amount of the active ingredient in products. Results of these studies have ranged from none or subclinical amounts of the product located to several times that suggested as "standard." [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] One last complication is specific to plant-based products. For many botanical products the portion of the plant that confers activity is in question. Some companies may use the entire plant, or just the leaves, sap, roots, stems, fruit or berries, or any combination of plant sections. Herbal experts have even speculated that components of the entire plant act in a synergistic fashion to cause the desired effect, and some products even combine different herbs together (see Table 2 , page 416).
ss Options for Managed Care Organizations and Pharmacists
In light of these issues, MCOs and pharmacists have several options. At one extreme, they may choose to avoid the naturalproduct issue entirely and deal only with adverse reactions that 
Managing Natural Products
• The active ingredient(s) may not be known.
• The exact mechanism of action of many natural products is unknown or is in question.
• Studies on biopharmaceutics, pharmacokinetics, and pharmacodynamics are often lacking.
• Data on use in pregnancy and lactation are limited.
• Products may not be standardized for purity or potency.
• Products may contain multiple ingredients.
• Products may be adulterated.
• Product dosages may not be standardized (for many products, no dose-ranging studies have been conducted).
• Products may be misidentified (or there may be variations between the label and the package contents).
• Crop conditions may cause batch-to-batch and year-to-year variability in the concentration and milligram weight of the active ingredients in these products.
• Studies and information on children, the elderly, those with renal impairment, etc., are lacking.
TABLE 1
Limitations of Current Natural Products cause members or patients to use resources or ask questions. However, without information and guidance, patients may not consider these products to be "medications" and may not report product use and associated problems to pharmacists and physicians. Or, at the other extreme, MCOs and pharmacists may embrace natural products, recommending their use when reasonable or even providing a coverage benefit for natural products and natural-product practitioners. Of course, there are many options between the extremes. Once an option is selected, that option may be steadfastly maintained, or practitioners and organizations may chose to allow the patient and the circumstance to dictate additional choices. Each choice is associated with potential risks and benefits for both patients and the MCO or pharmacist (See Table 3 , above). When natural products are recommended or provided as a covered option in health care, patients may have increased satisfaction with their health, their health care coverage, and their health care providers, and they may experience improved health outcomes. Additionally, the use of the prescription-medication benefit may decrease, and in many cases, the decrease may be appropriate.
Managing Natural Products

Product Documented Quality Problem
Echinacea A study examined 25 products and found that only 14 (56%) passed quality testing.
Ginkgo A study examined 32 ginkgo products and only 25 passed the basic criteria for content.
Ginseng A study examined 22 products and found that only 9 met quality and purity standards. A recent study looked at 25 products in the United States and found that only 11 products had specific labeling as to the concentration; six contained low concentrations, five contained high concentrations. Glucosamine and chondroitin Fourteen products containing glucosamine hydrochloride or glucosamine sulfate, and 11 products containing chondroitin were studied. The contents varied from 0%-115%. In another study of 25 products tested, nearly one-third did not pass testing standards. Melatonin
One study examined the quality of 11 melatonin products and found a wide variation in the quality of the products. Another examined 19 products and found that only 9 passed the quality criteria. St. John' s wort A study showed that 7 of the 21 products, one-third, did not pass testing for quality. Five of the products contained unacceptably high levels of cadmium. (Cadmium naturally accumulates as the St. John' s wort plant grows.) Only 2 of the 21 products mentioned hyperforin content, and one had suboptimal amounts.
Saw palmetto
Only 17 of 21 products tested were of adequate quality.
Valerian
In a study that examined 17 products, only 9 passed the quality test. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Source: See references 4-14
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Ten References for Information on Natural Medicines
Other patients may experience severe adverse effects. For example, in 1992, prior to DSHEA, the FDA warned several major manufacturers to stop producing dietary supplements containing guar gum after numerous reports of health problems and at least one death from esophageal obstruction associated with the products. 15 In 1994, the year that DSHEA was approved, Jin Bu Huan herbal tablets, which were promoted as a sedative, were directly linked to severe liver toxicity in both adults and children. 15 More recently, reports of injury and death in adolescents and young adults due to use and misuse of ma-huang or ephedra have caused the FDA to restrict the advertising practices of manufacturers. 15 Some of the risks associated with natural products can be eliminated or decreased with close attention to quality. Whenever possible, natural products should meet the same standards as FDA-approved pharmaceuticals. At a minimum, these standards should include the presence of lot numbers, expiration dates, 
TABLE 5
Free Alternative-Medicine Web Sites
Comment
Web site that contains a list of alternative Web sites. The page has links to databases, Internet resources, newsgroups and mailing lists, and government resources. All areas of alternative and complementary medicine are covered.
A commercial site that publishes several newsletters such as "Alternative Medicine Alert." Can search for write-ups on alternative-medicine topics.
"Meta-Site" for alternative medicine and is international in scope. It provides a broad collection of Internet resources in the field of alternative medicine. The page is organized by treatment categories. The links are from education, organizations, government, and commercial sponsors.
Information database where you can search for short write-ups. Some alternative medicine topics. Directed toward consumers.
Sponsored by the National Library of Medicine, MedlinePlus is directed toward consumers. The list primarily includes government resources. There is also a link to search Medline for articles on alternative medicine.
Information database where you can search for short write-ups. Some alternative medicine topics.
Allows you to search 180,000 bibliographic citations from 1963-1999. Citations extracted from the NIH Medline Database. Some abstracts listed.
Allows you to search the IBIDS database. This is the International Bibliographic Information on Dietary Supplements. It has international, scientific literature on dietary supplements, including vitamins, minerals, and botanicals. It currently contains more than 300,000 citations and abstracts. It was developed and will be maintained by the Office of Dietary Supplements at the NIH.
This site focuses on health-related frauds, myths, fads, and fallacies that are often propagated via the Internet and the media. There is an alternative medicine section that has a variety of topics such as legal and specific misleading information. There is also a list of nonrecommended references including books, individuals, periodicals, and Web sites.
A commercial site that has a list of alternative medicines (herbs, homeopathic, vitamins) from A to Z. Provides fairly detailed monograph-type information including dose and drug interactions. Referenced. Updated at an unknown frequency.
This site contains extensive resources for the most commonly referred to types of alternative medicine. The Herbal Medicine link includes an online version of Materia Medica, which contains monographs of many of the herbs used for treatment. Each monograph contains indications and doses; many contain references.
A commercial site that includes an alphabetical list of herbal remedies, drug-herb interactions, and herbal treatments for specific conditions.
A commercial site that has monographs on herbs, homeopathic and Chinese medicines. Referenced. Updated at an unknown frequency.
Sponsoring Organizations
Alternative standardized ingredients, exact contents including weights or volumes and concentrations, and contact information of the manufacturer. Ideally, pharmacists and other clinicians making recommendations to patients or coverage decisions should first be able to review product literature and double-blinded randomized, placebo, and gold-standard controlled clinical trials. In many cases that information is not available. As with OTC and prescription products, choices of which products and/or product lines to recommend or provide coverage for may be based on the manufacturer' s reputation. Large pharmaceutical companies are beginning to manufacture and market natural products. This option may some day allow the inclusion of reputable natural products with good quality-assurance processes in negotiated groupings or bundles. Until then, practitioners must be familiar with current products and the literature and information resources available for making decisions. Fortunately there are growing numbers of resources available to aid practitioners as they struggle with the tough decisions on natural products.
ss Information Resources
The amount of information concerning natural products has grown exponentially, making it almost impossible for reviewers to check every reference. However, there are a number of good references available in hard copy, on CD-ROM, and online. Some are listed in Table 4 , page 417, and Table 5 , page 418. These references are listed in alphabetical order by title rather than in order of importance. As with the natural products themselves, several key components should be examined when evaluating an information resource for natural products. These components include the reputations of the publisher, editors, and authors; the frequency with which the reference is updated; and whether the information is referenced. These key points should help to determine whether the information is current, correct, and unbiased, but cannot guarantee that. Reviewers will always need to use clinical judgment when new references or information sources are encountered.
ss Conclusion
Even with all of the questions that have been raised in the past ten years regarding natural products, there remains a common misconception among some health professionals, the public, and, based on the intent of DSHEA, some members of the U.S. Congress. That misconception is that "natural means safe." Historically, this has not always proven to be true. And, recently reports of illnesses and deaths attributed to the use or misuse of natural products have increased. When natural products are recommended or provided, some of the inherent risks can be minimized by insisting on products from manufacturers that adhere to good manufacturing practices and those that have a reputation for consistently high-quality products. Risks to patients can be reduced when reliable information and guidance is provided by health care professionals. In the absence of quality information from trained health care providers, patients may turn to other sources. Potential sources include family members, friends, the Internet, employees of exercise and nutrition centers and health food stores, advertisements in popular magazines, and brochures developed by naturalproduct manufacturers.
The popularity of natural products is likely to grow , and MCOs and pharmacists are well positioned to take an active role in the safe and effective use of natural products. However, there is a lack of consensus in the medical community about the use of natural products rather than, or in addition to, medications. The points to consider include, but are not limited to, potential therapeutic uses, probable effectiveness, appropriate doses, monitoring parameters, adverse effects, potential interactions, the risk of adulteration or contamination, and the risk to patients and practitioners when standard medical practices are not followed. Therefore, it is important whenever natural products are recommended or provided, that they be produced by reputable manufacturers of high-quality products that meet the standards for good manufacturing practices and product documentation. In addition, practitioners must use as many reliable resources as possible to support the ongoing study of these products and to help ensure that their decisions are made using correct and up-to-date information.
